Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus intensive induction therapy in children with first relapsed T-cell acute lymphoblastic leukemia
ChiCTR2000033973Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dasatinib window therapy response, Mid-induction minimal residual disease response and 2 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
dasatinib
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on ChiCTR2000033973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033973.